Review Article Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review

doi:10.1016/j.jmii.2021.01.001

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 其他文獻 > Item 310902500/24232

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24232

Title:	Review Article Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review
Authors:	Teng, CLJ;Wang, PN;Chen, YC;Ko, BS
Keywords:	Allogeneic hematopoietic stem cell transplantation;Cytomegalovirus;Prophylaxis;Preemptive;Ganciclovir
Date:	2021
Issue Date:	2022-08-05T10:45:12Z (UTC)
Publisher:	ELSEVIER TAIWAN
ISSN:	1684-1182
Abstract:	Because of the high incidence of cytomegalovirus (CMV) seropositivity in the population, CMV infection is a common and severe complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Taiwan. Here we propose a CMV management strategy for patients undergoing allo-HSCT from the Taiwanese perspective, which focuses on the epidemiology, diagnosis, monitoring, prophylaxis, and treatment of CMV infection after allo-HSCT. In terms of CMV monitoring, weekly CMV monitoring with the COBAS (R) AmpliPrep system is the standard approach because the pp65 CMV antigenemia assay has a lower sensitivity than CMV monitoring with the COBAS (R) AmpliPrep system. However, pp65 CMV antigenemia assay has a better correlation with clinical symptoms in immunocompromised patients. A 14-week prophylactic course of letermovir is recommended for allo-HSCT recipients in Taiwan, especially for recipients of hematopoietic stem cells from mismatched unrelated and haploidentical donors. Preemptive ganciclovir therapy should be initiated when the CMV viral load exceeds 1000 copies/mL, and should not be discontinued until CMV DNA is no longer detectedin the blood. For allo-HSCT recipients who have CMV-related diseases, ganciclovir with or without CMV-specific intravenous immunoglobulin is the standard of care. The limited availability of foscarnet, an alternative for patients who are not responsive to or cannot tolerate ganciclovir, is a crucial issue in Taiwan. For pediatric allo-HSCT recipients, more data are needed to propose a CMV management recommendation. Copyright (c) 2021, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
URI:	http://dx.doi.org/10.1016/j.jmii.2021.01.001 https://www.webofscience.com/wos/woscc/full-record/WOS:000664639400001 https://ir.csmu.edu.tw:8080/handle/310902500/24232
Relation:	JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION ,2021 ,v54 ,issue3 ,p348-348
Appears in Collections:	[中山醫學大學研究成果] 其他文獻

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	290	View/Open

Loading...